Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2011

01.01.2011 | Original Article

Effectiveness of the Immunofecal Occult Blood Test for Colorectal Cancer Screening in a Large Population

verfasst von: Haiyun Yang, Zhizheng Ge, Jun Dai, Xiaobo Li, Yunjie Gao

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Guaiac tests are the most widely used tests to detect colorectal cancer (CRC). However, their sensitivity is relatively low and results may be affected by various factors. Immunofecal occult blood test (IFOBT) is specific for human hemoglobin and does not require dietary restrictions.

Aims

The aim of this study was to evaluate the effectiveness of IFOBT for the screening of precancerous lesions and CRC.

Methods

From July 2006 to June 2007, IFOBT was performed on 5,919 adults who received periodic health examinations in our hospital. The positive cases were examined by colonoscopy and a double-contrast barium enema. Diagnosis was confirmed by histopathological analysis.

Results

Positive IFOBT was detected in 314 of 5,919 cases (5.30%). Further examinations were made in 264 IFOBT-positive cases. Of these, 116 cases with colorectal cancer (16 cases) or precancerous lesions (94 cases with colorectal adenomatous polyps and 6 cases with active ulcerative colitis) were detected. The total detection rate of CRC and precancerous lesions was 43.94% (116/264). TNM classification of 16 CRC cases was as follows: TNM I in eight cases (50.00%), TNM II in seven cases (43.75%) and TNM III in one case (6.25%), indicating IFOBT can detect CRC in the early stages.

Conclusion

Regular IFOBT can detect precancerous lesions and CRC in early stages and can thus reduce mortality from CRC.
Literatur
1.
Zurück zum Zitat Daniel L, Joseph J, Robert H, et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–1403.CrossRef Daniel L, Joseph J, Robert H, et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–1403.CrossRef
2.
Zurück zum Zitat Autier P. Should organised faecal occult blood test screening be established? Ann Oncol. 2002;13(1):57–60.CrossRefPubMed Autier P. Should organised faecal occult blood test screening be established? Ann Oncol. 2002;13(1):57–60.CrossRefPubMed
3.
Zurück zum Zitat Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol. 2002;13(1):51–56.CrossRefPubMed Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol. 2002;13(1):51–56.CrossRefPubMed
4.
Zurück zum Zitat Bleiberg H. Hemoccult should no longer be used for the screening of colorectal cancer. Ann Oncol. 2002;13(1):44–46.CrossRefPubMed Bleiberg H. Hemoccult should no longer be used for the screening of colorectal cancer. Ann Oncol. 2002;13(1):44–46.CrossRefPubMed
5.
Zurück zum Zitat Levi Z, Hazazi R, Rozen P, et al. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23(9):1359–1364.CrossRefPubMed Levi Z, Hazazi R, Rozen P, et al. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23(9):1359–1364.CrossRefPubMed
6.
Zurück zum Zitat Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23(3):309–313.CrossRefPubMed Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23(3):309–313.CrossRefPubMed
7.
Zurück zum Zitat Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13(1):71–75.CrossRefPubMed Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13(1):71–75.CrossRefPubMed
8.
Zurück zum Zitat Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53(1):44–55.CrossRefPubMed Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53(1):44–55.CrossRefPubMed
9.
Zurück zum Zitat Labianca R, Beretta GD, Mosconi S, et al. Colorectal cancer: screening. Ann Oncol. 2005;16(Suppl 2: ii):127–132. Labianca R, Beretta GD, Mosconi S, et al. Colorectal cancer: screening. Ann Oncol. 2005;16(Suppl 2: ii):127–132.
10.
Zurück zum Zitat Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52(3):323–326.CrossRef Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52(3):323–326.CrossRef
11.
Zurück zum Zitat Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–1109.CrossRefPubMed Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–1109.CrossRefPubMed
12.
Zurück zum Zitat Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota colon cancer control study. N Eng J Med. 1993;328:1365–1371.CrossRef Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota colon cancer control study. N Eng J Med. 1993;328:1365–1371.CrossRef
13.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal—occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal—occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed
14.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colon cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colon cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed
15.
Zurück zum Zitat La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002;13(1):31–34.CrossRefPubMed La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002;13(1):31–34.CrossRefPubMed
16.
Zurück zum Zitat Yan HY, Ge ZZ. Research status of fecal occult blood test in the early diagnosis of colorectal cancer. Chin J Gastroenterol. 2006;11(6):376–378. Yan HY, Ge ZZ. Research status of fecal occult blood test in the early diagnosis of colorectal cancer. Chin J Gastroenterol. 2006;11(6):376–378.
17.
Zurück zum Zitat Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002;94(15):1126–1133.PubMed Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002;94(15):1126–1133.PubMed
18.
Zurück zum Zitat Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422.CrossRefPubMed Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422.CrossRefPubMed
19.
Zurück zum Zitat Yeazel MW, Church TR, Jones RM, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13(4):654–657. (Erratum in: Cancer Epidemiol Biomarkers Prev. 2004;13(9):1550).PubMed Yeazel MW, Church TR, Jones RM, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13(4):654–657. (Erratum in: Cancer Epidemiol Biomarkers Prev. 2004;13(9):1550).PubMed
20.
Zurück zum Zitat Scales CD Jr, Fein S, Muir AJ, et al. Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission. J Clin Gastroenterol. 2006;40(10):913–918.CrossRefPubMed Scales CD Jr, Fein S, Muir AJ, et al. Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission. J Clin Gastroenterol. 2006;40(10):913–918.CrossRefPubMed
21.
Zurück zum Zitat Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.CrossRefPubMed Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.CrossRefPubMed
22.
Zurück zum Zitat Rex DK, Overhiser AJ, Chen SC. Estimation of impact of American college of radiology recommendations on CT clonograph reporting for resection of high-risk adenoma findings. Am J Gastroenterol. 2009;104:149–153.CrossRefPubMed Rex DK, Overhiser AJ, Chen SC. Estimation of impact of American college of radiology recommendations on CT clonograph reporting for resection of high-risk adenoma findings. Am J Gastroenterol. 2009;104:149–153.CrossRefPubMed
23.
Zurück zum Zitat Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13(1):47–50.CrossRefPubMed Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13(1):47–50.CrossRefPubMed
24.
Zurück zum Zitat Mizutani S, Fumitani M, Kaneshiro E, et al. Fundamental evaluation of fully automated fecal occult blood analyzer “OC-SENSORμ”. J Med Pharm Sci. 2002;47(5):769–773. Mizutani S, Fumitani M, Kaneshiro E, et al. Fundamental evaluation of fully automated fecal occult blood analyzer “OC-SENSORμ”. J Med Pharm Sci. 2002;47(5):769–773.
25.
Zurück zum Zitat Noboru G, Michiko F, Keiko I, et al. Basic study of OC-SENSOR μ, a compact fully automated immunochemistry analyzer for fecal occult blood tests. J Clin Lab Inst Reag. 2002;25(1):57–62. Noboru G, Michiko F, Keiko I, et al. Basic study of OC-SENSOR μ, a compact fully automated immunochemistry analyzer for fecal occult blood tests. J Clin Lab Inst Reag. 2002;25(1):57–62.
26.
Zurück zum Zitat Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood-screening test. Am J Gastroenterol. 2005;100(11):2519–2525.CrossRefPubMed Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood-screening test. Am J Gastroenterol. 2005;100(11):2519–2525.CrossRefPubMed
27.
Zurück zum Zitat Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9(3):99–103.CrossRefPubMed Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9(3):99–103.CrossRefPubMed
28.
Zurück zum Zitat Robert A, Vilma C, Harmon J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2006;56:11–25.CrossRef Robert A, Vilma C, Harmon J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2006;56:11–25.CrossRef
29.
Zurück zum Zitat Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25 (quiz 49–50).CrossRefPubMed Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25 (quiz 49–50).CrossRefPubMed
30.
Zurück zum Zitat U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290.
Metadaten
Titel
Effectiveness of the Immunofecal Occult Blood Test for Colorectal Cancer Screening in a Large Population
verfasst von
Haiyun Yang
Zhizheng Ge
Jun Dai
Xiaobo Li
Yunjie Gao
Publikationsdatum
01.01.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1264-8

Weitere Artikel der Ausgabe 1/2011

Digestive Diseases and Sciences 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.